Obeticholic acid

(Ocaliva)

Obeticholic acid

Drug updated on 11/13/2023

Dosage FormTablet (oral; 5 mg, 10 mg)
Drug ClassFarnesoid X receptor agonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with primary biliary cholangitis (PBC) without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension, either in combination with ursodeoxycholic acid (UDCA) with an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA.

Product Monograph / Prescribing Information

Document TitleYearSource
Ocaliva (obeticholic acid) Prescribing Information.2022Intercept Pharmaceuticals, Inc., New York, NY

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines